Clinical Trial Update: LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine [Phase 1]

View source ↗

Summary

This update notes the completion of a Phase 1 trial evaluating LEISH-F3 vaccines with GLA-SE or MPL-SE adjuvants for leishmaniasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leishmaniasis

Drugs mentioned

• LEISH-F3 + GLA-SE
• LEISH-F3 + MPL-SE

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Leishmaniasis | Phase 1 | Status: COMPLETED